We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Om39.0
Omega-3 Research
Probably helps
987 peer-reviewed studies
What the evidence says
Likely helps
Omega-3 appears to help in 15 of 18 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 2015–2026 with a typical study size of 860 participants.
Based on 981 studies · 275 meta-analyses · 593 RCTs · 452,721 total participants
Confidence
High confidence
What the studies found
15helped2unclear1didn't help· 963 more without graded effect data
By outcome
Heart & blood pressureImproved triglycerides and cardiovascular markers within 4-8 weeks · 4-8 weeks
Likely helps825 studies
Therapeutic & clinical
Likely helps151 studies
Women's healthMay help reduce menstrual discomfort and PMS symptoms · 1-3 cycles · Provides essential nutrients for healthy pregnancy · Ongoing · Anti-inflammatory support during menopausal transition · 4-8 weeks
Likely helps106 studies
Cognitive functionDHA is critical structural component of brain, supports memory · 8-12 weeks
Focus & attentionImproved cognitive function · 4-12 weeks
Mostly mechanism / observational4 studies
Fertility & reproductiveMay support reproductive health and fertility markers · 4-12 weeks
Mostly mechanism / observational3 studies
Sleep & insomniaHigher omega-3 status associated with better sleep quality · 8-12 weeks
Mostly mechanism / observational3 studies
By the numbers
Pulled from 55 studies with measurable effects
Likely real effects
83%
across studies
People studied
453k
typical study: 860 people
Strongest designs
868
275 pooled, 593 randomised
Showed benefit
83%
15/18 studies
How long studies ran
1–3 months
2
3+ months
5
Populations Studied
General population4
Pregnant women3
Cardiovascular patients3
Migraine patients2
Active research area
700 studies in the last 5 years · Latest meta-analysis: 2026
201520202026
1muscle strength, endurance, and recoveryMeta-Analysisn=1,211 · large study2026
In plain English: These findings reveal an outcome-specific efficacy pattern supporting targeted supplementation strategies aligned with primary training objectives in athletic populations.
Wang Z et al. · Nutrients (2026)
The analysis incorporated 35 trials enrolling 1211 participants.
Network consistency assessment revealed no significant disagreement between direct and indirect evidence across all outcomes.
These findings reveal an outcome-specific efficacy pattern supporting targeted supplementation strategies aligned with primary training objectives in athletic populations.
2Depressive disorder symptomsMeta-Analysisn=17,437 · very large study2025
In plain English: This extensive systematic review and NMA of nutraceuticals for treating depressive disorders indicated a number of nutraceuticals that could offer benefits, either as adjuncts or monotherapies.
Cheng YC et al. · Psychological medicine (2025)
Adjunctive nutraceuticals consistently showed better efficacy than antidepressants (ADT) alone in outcomes including SMD, remission, and response.
This extensive systematic review and NMA of nutraceuticals for treating depressive disorders indicated a number of nutraceuticals that could offer benefits, either as adjuncts or monotherapies.
3Anxiety symptomsMeta-Analysisn=2,189 · very large study2024
In plain English: The present dose-response meta-analysis suggested evidence of very low certainty that supplementation with omega-3 fatty acids may significantly improve anxiety symptoms, with the greatest improvements at 2 g/d.
Bafkar N et al. · BMC psychiatry (2024)
Large benefit
← WorseNo effectBetter →
Each 1 gram per day supplementation with omega-3 fatty acids resulted in a moderate decrease in anxiety symptoms (SMD: -0.70, 95%CI: -1.17, -0.22; GRADE = low).
The non-linear dose-response analysis indicated the greatest improvement at 2 g/d (SMD: -0.93, 95%CI: -1.85, -0.01), and that supplementation in a dose lower than 2 g/d did not affect anxiety symptoms.
Omega-3 fatty acids did not increase adverse events (odds ratio: 1.20, 95%CI: 0.89, 1.61; GRADE = moderate).
4Preeclampsia riskMeta-Analysisn=8,004 · very large study2024
In plain English: Based on the results of the present study, the consumption of omega-3 supplementation and fish oil significantly reduces the risk of developing preeclampsia.
Rajati M et al. · Clinical nutrition ESPEN (2024)
Based on the results of the present study, the consumption of omega-3 supplementation and fish oil significantly reduces the risk of developing preeclampsia.
5Migraine prophylaxisMeta-Analysisn=6,616 · very large study2024
In plain English: Migraine is a highly prevalent neurologic disorder with prevalence rates ranging from 9% to 18% worldwide.
Tseng PT et al. · Advances in nutrition (Bethesda, Md.) (2024)
No clear effect
← WorseNo effectBetter →
Migraine is a highly prevalent neurologic disorder with prevalence rates ranging from 9% to 18% worldwide.
Current pharmacologic prophylactic strategies for migraine have limited efficacy and acceptability, with relatively low response rates of 40% to 50% and limited safety profiles.
Forty RCTs were included (N = 6616; mean age = 35.0 y; 78.9% women).
6Anxiety and depressionMeta-Analysisn=1,426 · large study2023
In plain English: Only one study reported significant reduction in anxiety severity with 2.1 g/day EPA (85.6% of total EPA + DHA), therefore meta-analysis was not possible.
Kelaiditis CF et al. · Prostaglandins, leukotrienes, and essential fatty acids (2023)
Only one study reported significant reduction in anxiety severity with 2.1 g/day EPA (85.6% of total EPA + DHA), therefore meta-analysis was not possible.
These results support the therapeutic potential of EPA in depression at proportions ≥ 60% of total EPA + DHA and doses ≥ 1 g/day and < 2 g/day.
7Depressive symptomsSystematic Reviewn=4,500 · very large study2021
In plain English: Our primary analyses may suggest a small-to-modest, non-clinically beneficial effect of n-3PUFAs on depressive symptomology compared to placebo; however the estimate is imprecise, and we judged the certainty of the evidence on which this result is based to be low to very low.
Appleton KM et al. · Cochrane Database of Systematic Reviews (2021)
At present, we do not have sufficient high-certainty evidence to determine the effects of n-3PUFAs as a treatment for MDD.
Primary analyses may suggest a small-to-modest, non-clinically beneficial effect of n-3PUFAs on depressive symptomology compared to placebo.
More complete evidence is required for both the potential positive and negative effects of n-3PUFAs for MDD.
9Multiple sclerosis relapsing rate and inflammatory markersSystematic Reviewn=5,554 · very large study2021
In plain English: These roles were attributed to their beneficial effects on inflammatory markers, glutathione reductase, reducing the relapsing rate, and achieving balanced omega-6 to omega-3 ratios.Conclusion: Omega-3 and fish oils supplementations have beneficial effects on reducing the relapsing rate, inflammatory markers, and improving the quality of life for MS patients.
AlAmmar WA et al. · Nutritional neuroscience (2021)
The inclusions were studies performed on humans both male and female, aged 18 years at minimum, diagnosed with MS according to McDonald 2010 criteria.
Otherwise, all studies were excluded.Results: A total of 5554 studies were screened and seven were thoroughly focused on as they typically met the inclusion criteria.
These studies showed the beneficial roles of fish oil supplementation and omega-3 fatty acids in improving the quality of life of MS patients.
In plain English: The find-ings highlight the heterogeneity in responses to omega-3 fatty acid supplementation and emphasize the need for cautious interpretation.
Fei L et al. · Asia Pacific journal of clinical nutrition (2024)
The meta-analysis revealed a neutral overall effect size of omega-3 fatty acid supplementation on proteinuria levels, assessed under both common and random effect models.
Despite the lack of statistically significant evidence supporting the efficacy of omega-3 fatty acids in reducing proteinuria, the variability in interventions and patient populations suggests potential individual responses.
The find-ings highlight the heterogeneity in responses to omega-3 fatty acid supplementation and emphasize the need for cautious interpretation.
11Cardiovascular events and coronary revascularizationMeta-Analysisn=144 · medium study2024
In plain English: Omega-3 fatty acid supplementation reduced the risk of cardiovascular events and coronary revascularization, regardless of background statin use.
Dinu M et al. · European journal of preventive cardiology (2024)
Noticeable benefit
← WorseNo effectBetter →
Likely real
Lower risk was still observed in trials where most participants (≥60%) were on statin therapy.
Compared with DHA + EPA, EPA alone showed a further significant risk reduction of revascularizations (0.76, 95% CI 0.65-0.88; P = 0.0002; P-interaction = 0.005) and all outcomes except HF.
Omega-3 fatty acid supplementation reduced the risk of cardiovascular events and coronary revascularization, regardless of background statin use.
13Depressed moodMeta-AnalysisCited 48×n=4,605 · very large study2018
In plain English: In the well-being mental health group, the Hedges g was 0.12 (95% confidence interval, -0.05 to 0.29), which indicated no significant effect of n-3 PUFA supplementation on depressed mood compared w...
Bae JH et al. · Nutrition research (New York, N.Y.) (2018)
Huge benefit
← WorseNo effectBetter →
In the well-being mental health group, the Hedges g was 0.12 (95% confidence interval, -0.05 to 0.29), which indicated no significant effect of n-3 PUFA supplementation on depressed mood compared with placebo.
In the depressive group, the pooled Hedges g was -0.94 (95% CI, -1.37 to -0.50]) for the random-effects model, which indicated a large effect of n-3 PUFA supplementation on those with depressed mood compared with placebo.
Although this review shows that omega-3 fatty acids are effective in the treatment of elderly depressed patients, the benefits of omega-3 fatty acid supplementation were significant only in the elderly patients with mild to moderate depression.